Skip to content
lifestyle.realie.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oryzon Genomics, S.A.
ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
March 12, 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
February 27, 2026
ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia
February 24, 2026
ORYZON to Participate in Upcoming Events in February and March
February 19, 2026
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
February 12, 2026
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
February 9, 2026
←
Previous Page
1
2